{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-21-000021","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2021-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.132506+00:00","generated_at":"2026-06-28T23:30:25.018195+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcutis submits NDA to FDA for roflumilast cream in plaque psoriasis","bullets":["Submitted NDA for roflumilast cream (ARQ-151) to FDA for mild-to-severe plaque psoriasis.","Indication covers adults and adolescents; submission date October 4, 2021.","Roflumilast cream is a topical PDE4 inhibitor, a novel mechanism for psoriasis."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-21-000021","json":"https://secwatch.observer/filing/0001787306-21-000021.json","markdown":"https://secwatch.observer/filing/0001787306-21-000021.md","text":"https://secwatch.observer/filing/0001787306-21-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730621000021/0001787306-21-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730621000021/arqt-20211004.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:30:25.018195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}